By Shreesh BiradarIn October, the Nifty 50 and Nifty Midcap 100 indices declined by 2.8% and 4.3%, respectively. This volatility, especially in mid-cap stocks, has shifted the focus back to value and growth investing. Tensions in the Middle East, particularly the Hamas-Israel conflict, have led to a surge in oil prices to $92 per barrel, However the oil prices reverted back to $81 in the first half of November. India’s retail inflation eased to a five month low of 4.9% in October further.
Despite these fluctuations, Indian equity mutual funds have recorded a net inflow of Rs 12,932 crore in October. Large-cap funds saw an inflow of Rs 724 crore after six months of outflows. Small-cap stocks registered the highest inflow of Rs 4,495 crore, followed by mid-cap stocks at Rs 2,409 crore.

Aurobindo Pharma’s MF holdings increase to 740.2 lakh shares in October
Aurobindo Pharma sees growth with US market stabilization
Aurobindo Pharma (AUROPHARMA) is pharmaceutical firm and a major manufacturer of active pharmaceutical ingredients (APIs), branded drugs, and generic pharmaceuticals. US and European markets account for nearly 75% of its revenue. The firm has received 466 Abbreviated New Drug Approvals (ANDAs) from the US Food and Drug Administration (USFDA) so far.
Aurobindo Pharma’s Q2FY24 revenue increased by 25.8% YoY and net profit by 83.2%. The profit growth was aided by margin expansion due to lower raw material costs and price stabilization of high-margin drugs. The company’s overall growth was led by antiretroviral (ARV) drugs and oral drugs. The firm plans to launch Eugia, a generic injectable with a potential revenue stream of $520 million, and has other drugs in the pipeline, including Trastzumab biosimilar, Pen–G injectable, and gRevlimid.
Aurobindo Pharma recently launched a greenfield facility for injectables in Visakhapatnam and has entered into a partnership with Singapore-based Hilleman Labs for pediatric vaccines. With drug shortages in the US and falling competition, the company expects prices to stabilize. The firm is expected to grow at an 11% CAGR from FY24 to FY25 and will also be aided by lower raw material costs, leading to margin expansion.
Fund managers who bought shares of Aurobindo Pharma
Fund managers who added shares of Aurobindo Pharma to their portfolios include Chirag Setalvad and Dhruv Muchhal for HDFC Mid-Cap Opportunities, Daylynn Pinto and Nishita Shah for Bandhan Sterling Value Fund, Sankaran Naren and Dharmesh Kakkad for ICICI Prudential Value Discovery Fund, Vasav Sahgal and Ankit A Pande for Quant Tax Plan Fund, and Manish Lodha and Abhinav Khandelwal for Mahindra Manulife Mid Cap Fund.
InterGlobe Aviation eyes growth with infra boost
InterGlobe Aviation (INDIGO) is a major player in the air transportation business, offering both passenger and cargo services. Dominating the domestic market with a 54% share, IndiGo serves 78 domestic and 32 international destinations with a fleet of 320 aircraft.
IndiGo reported a 19.6% increase in revenue in Q2FY24, led by higher volumes. The airline clocked an 83.3% load factor (79.1% in Q2FY23), and saw margin expansion aided by higher ticket prices. The Indian government's push for aviation infrastructure and the rising number of airports have boosted passenger traffic. Capitalizing on its low-cost model and network, IndiGo holds a 26% market share in the international passenger market. The company plans to double its fleet size to 600 by 2030, aiming to boost connectivity, attract more passengers, and drive double-digit growth in the medium term.
Fund managers who bought shares of InterGlobe Aviation
Fund managers who added shares of InterGlobe Aviation to their portfolios include Anish Tawakley and Vaibhav Dusad for ICICI Prudential Bluechip Fund, Abhishek Bisen and Devender Singhal for Kotak Multi Asset Allocation Fund, Sankaran Naren and Anuj Tagra for ICICI Prudential Multi-Asset Fund, Neelesh Surana for Mirae Asset Tax Saver Fund, and Pranav Gokhale and Shridatta Bhandwaldar for Canara Robeco Flexi Cap Fund.
CSB Bank targets market share expansion through new branches
CSB Bank (CSBBANK), owned by Fairfax, is one of the oldest private sector banks in India. With roots in Kerala, the bank specializes in gold and small and medium enterprise (SME) lending. It caters to 2.2 million customers through 704 branches. Around 58% of its branches are located in semi-urban and rural areas. The bank has a major presence in South India and a loan book size of Rs 22,468 crore.
CSB’s net interest margin contracted by 60 bps QoQ in Q2FY24. This led to a 5.5% decrease in its net interest income. However, the bank managed to partly offset this decline through its fee income from insurance distribution. Facing stiff competition in gold loans from nationalized banks and slowing growth in SME lending due to rising interest rates, CSB Bank is trying to diversify into retail banking. The bank plans to double its branch count by FY30. The bank has so far been able to balance the increase in the cost of funds with higher yields.
Fund managers who bought shares of CSB Bank
Fund managers who added shares of CSB Bank to their portfolios include Karthikraj Lakshmanan for UTI MNC Fund, R Srinivasan and Mohit Jain for SBI Magnum Global Fund, and Mehul Dama for Nippon India Nifty Smallcap 250 Index Fund. Fresh buys were done by Piyush Baranwal and Ramesh Mantri for WhiteOak Capital Flexi Cap Fund, and Shiv Chanani and Miten Vora for Baroda BNP Paribas Small Cap Fund.
CreditAccess Grameen Bank expands reach and loan portfolio
CreditAccess Grameen (CREDITACC), a finance firm specializing in services for women, operates across 14 states and 1,826 branches. The NBFC has a gross AUM of Rs 22,488 crore, catering to 45.9 lakh customers. The firm has a strong rural presence and is expanding into non-microfinance businesses.
The company reported a net income growth of 49.6% YoY in Q2FY24. Its AUM grew by 36% YoY, helped by higher customer addition and increasing ticket size. While the firm's net interest margins are expected to moderate in the future, its competitive lending rates (200-400 bps lower than its peers) have played a key role in customer retention. Branch expansions have contributed to its wider reach and customer additions.
CreditAccess Grameen plans to increase its AUM to Rs 50,000 crore in the next five years and expand its non-microfinance loan book to 25% from the current 10%. It also aims to add new categories like loan against property (LAP), vehicle loans and gold loans to non-microfinance loans.
Fund managers who bought shares of CreditAccess Grameen Bank
Fund managers who added shares of CreditAccess Grameen to their portfolios include Shreyash Devalkar and Vinayak Jayanath for Axis Small Cap Fund, Taher Badshah for Invesco India Smallcap Fund, and Shridatta Bhandwaldar and Amit Nadekar for Canara Robeco Emerging Equities Fund. Fresh buys were done by Vishal Mishra and Shridatta Bhandwaldar for Canara Robeco Equity Taxsaver Fund, and Shreyash Devalkar and Hitesh Das for Axis Growth Opportunities Fund.
Sobha expects robust launch pipeline and geo expansion to aid top line
Bangalore-based Sobha (SOBHA) is engaged in real estate construction, development, and sales. The company has developed townships, housing apartments and commercial real estate. It has also ventured into interior works, metal works and concrete products, providing backward integration.
Sobha’s Q2FY24 operational data indicated that it hit a lifetime high in pre-sales, reaching Rs 1,720 crore, with an average price realization of Rs 10,223 per square foot. The entire sales of Q2FY24 were in existing inventory, as the company did not have any new launches during this period.
But with a 15-million-square-foot launch pipeline planned for the next two years, the company is set for substantial revenue growth. The escalating real estate values in metro cities also contributes to higher price realization.
Sobha faces a legal challenge over allegations of forging a no-objection certificate from the municipal corporation, with home buyers claiming misappropriation of Rs 1,040 crore.
The firm's expansion into cities like Kochi and Gurugram has broadened its geographical footprint and contributed to its margin growth. This diversification is timely, coinciding with rising demand in the premium luxury segment.
Fund managers who bought shares of Sobha
Fund managers who added shares of Sobha to their portfolios include Ravi Gopalakrishnan and Rohit Seksaria for Sundaram Small Cap Fund, Vishal Gajwani and Dhaval Joshi for Aditya Birla Sun Life Small Cap Fund, and Satish Ramanathan and Asit Bhandarkar for JM Value Fund. Fresh buys were done by Daylynn Pinto and Nishita Shah for Bandhan Sterling Value Fund, and Ratish Varier and Sudhir Kedia for Sundaram Multi Cap Fund.

Granules India's MF holdings stand at 110.3 lakh shares in October
Granules India to boost future sales with higher capex
Granules India (GRANULES), based in Hyderabad, is a key player in the pharmaceutical industry, a specialist in the manufacture and sales of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs), and Finished Dosages (FDs). The company has seven manufacturing facilities and has filed 71 ANDA applications. The US accounts for nearly 53% of its total sales.
Currently, Granules India is undergoing a major capex cycle by investing in R&D and capacity expansion. It is also focusing on improving security systems around its technology, following a cyber security attack that resulted in revenue loss. Granules India plans to file complex products with high entry barriers in the US and Europe to boost its revenue streams. It also plans to commercialize its manufacturing facilities for Metformin and Paracetamol by FY25.
Fund managers who bought shares of Granules India
Fund managers who added shares of Granules India to their portfolios include Sanjeev Sharma and Vasav Sahgal, for Quant Business Cycle Fund, Mehul Dama for Nippon India Nifty Smallcap 250 Index Fund, and Kayzad Eghlim and Nishit Patel for ICICI Prudential Nifty Healthcare ETF. Fresh buys were done by Vasav Sahgal and Ankit A. Pande for Quant Tax Plan Fund, and Sanjeev Sharma and Vasav Sahgal for Quant Flexi Cap Fund.
Nazara Technologies prioritises inorganic expansion for revenue growth
Nazara Technologies (NAZARA), is a software & services firm offering a diverse gaming & sports media platform, operates across India, Africa, and North America. The company has offerings across the interactive gaming, eSports, ad-tech, and early learning ecosystems. The firm earns revenue through subscriptions and services. It generates nearly 52% of its revenue from the eSports segment.
The firm recently announced a plan to raise Rs 100 crore by issuing just over 14 lakh shares to Kamath Associates and NKSquared for Rs 714 per share. The funds are for capital requirements and acquisitions and investments in other companies.
The firm reported a 12.7% YoY growth in revenue for Q2FY24, aided by margin expansion due to lower spending on advertising. Its eSports and gamified early learning segments led the top-line expansion with 26% and 31% YoY growth, respectively.
Fund managers who bought shares of Nazara Technologies
Fund managers who added shares of Nazara technologies to their portfolios include Nimesh Chandan and Siddharth Chaudhary for Bajaj Finserv Flexi Cap Fund, Hardick Bora and Sanjay Bembalkar for Union Innovation & Opportunities Fund, and Mehul Dama for Nippon India Nifty Smallcap 250 Index Fund. Fresh buys were done by Rama Srinivasan and Mohit Jain for SBI Multicap Fund, and Ankit Agarwal and Deepesh Agarwal for UTI Innovation Fund.
Dixon Technologies India to boost revenue visibility through customer acquisition
Dixon Technologies (India) (DIXON) operates in the consumer electronic manufacturing space and offers design solutions for consumer durables, home appliances, lighting, mobile phones, medical equipment, etc. Dixon has 18 manufacturing facilities in India, spread across Uttar Pradesh, Uttarakhand and Andhra Pradesh.
Dixon Technologies is benefitting from the government’s PLI scheme, which covers its various manufacturing facilities. It derives 65% of its revenue from the consumer electronics and mobile divisions. The company has partnered with China-based mobile companies Xiaomi and Itel to manufacture smartphones in India, with operations expected to start in Q3FY24. Dixon has also added customers like Voltas Beko, which will aid revenue growth. The firm is also planning to design and develop its own products.
Fund managers who bought shares of Dixon Technologies
Additional shares of Dixon Technologies were added by Chirag Setalvad and Priya Ranjan forHDFC Mid-Cap Opportunities Fund, Kinjal Desai and Amar Kalkundrikar for Nippon India Vision Fund, and Shridatta Bhandwaldar and Amit Nadekar Canara Robeco Emerging Equities Fund, Niket Shah and Ankush Sood for Motilal Oswal Midcap Fund, and Ajay Tyagi for UTI Flexi Cap Fund.
BSE to diversify revenue with new derivative products
BSE (BSE) is one of India’s top two leading exchange groups. It facilitates capital-raising and trading in a range of financial instruments including equity, debt, derivatives, and mutual funds. It also provides a trading platform for small and medium enterprises (SMEs).
BSE reported a 46% YoY increase in its Q2FY24 revenue, led by a surge in transaction and clearing revenue. The exchange’s derivatives market share grew to 7.4% in September 2023 from 0% in April 2023. Its average daily trading volume in options, which was non-existent between January and May 2023, rose to Rs 26 lakh crore in September 2023. The launch of Bankex (Monday expiry) will cater to a larger addressable volume, potentially leading to further gains in market share.
Fund managers who bought shares of BSE
Fund managers who added shares of BSE to their portfolios include Sanjeev Sharma and Vasav Sahgal for Quant Small Cap Fund, and Nimesh Chandan and Siddharth Chaudhary for Bajaj Finserv Flexi Cap Fund. Fresh buys were done by Manish Lodha and Fatema Pacha for Mahindra Manulife Multi Cap Fund, Niket Shah and Rakesh Shetty for Motilal Oswal Long Term Equity Fund, and Mohit Jain and Milind Agrawal for SBI Banking & Financial Services Fund.
Mahanagar Gas aims for margin growth with lower CNG prices
Mahanagar Gas (MGL) is a city gas distribution utilities firm operating in Mumbai, its adjoining areas, and the Raigad district of Maharashtra. Nearly 70% of the company’s revenue is from CNG sales. The firm has 319 CNG stations under its banner.
The acquisition of Unison Enviro (UEPL) for Rs 531 crore has helped the firm in enhancing its geographical footprint. UEPL holds gas distribution rights across Ratnagiri, Chitradurga & Devangere, and Latur & Osmanabad. The firm reported 0.5% YoY revenue growth in Q2FY24. This modest increase is on account of a reduction in CNG prices. However, lower raw material costs have improved its margins.
Mahanagar Gas has also launched card-based schemes for CNG users to expand its market share. The government’s plan to raise the share of natural gas in India’s energy mix to 15% by 2030, up from the current 6%, is expected to boost MGL’s prospects.
Fund managers who bought shares of Mahanagar Gas
Fund managers who added shares of Mahanagar Gas to their portfolios include Amit Premchandani for UTI Dividend Yield Fund and Yogesh Patil and Dikshit Mittal for LIC MF Large & Mid Cap Fund. Fresh buys were done by Viral Shah and Dhaval Patel for NJ ELSS Tax Saver Fund, Kedar Karnik and Jay Kothari for DSP Equity Savings Fund, and Sumit Bhatnagar and Pratik Shroff for LIC MF Equity Savings Fund